{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:45:24Z","timestamp":1792615524782,"version":"4.5.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"29","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.vaccine.2021.05.073","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T09:35:15Z","timestamp":1622799315000},"page":"3852-3861","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Development of a platform-based approach for the clinical production of HIV gp120 envelope glycoprotein vaccine candidates"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4341-8899","authenticated-orcid":false,"given":"Leslie S.","family":"Wolfe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"James G.","family":"Smedley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1376-6024","authenticated-orcid":false,"given":"Niket","family":"Bubna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Althaf","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8099-0520","authenticated-orcid":false,"given":"Richard","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigma","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.vaccine.2021.05.073_b0005","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/cpt.1208","article-title":"HIV\/AIDS Vaccines: 2018","volume":"104","author":"Robinson","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.vaccine.2021.05.073_b0010","doi-asserted-by":"crossref","unstructured":"Gao Y, McKay PF, Mann JSF. Advances in HIV-1 Vaccine development. Viruses 2018; 10(4)","DOI":"10.3390\/v10040167"},{"key":"10.1016\/j.vaccine.2021.05.073_b0015","doi-asserted-by":"crossref","unstructured":"Medina-Ramirez M, Sanders RW, Sattentau QJ. Stabilized HIV-1 envelope glycoprotein trimers for vaccine use. Curr Opin HIV AIDS 2017; 12(3): 241-249","DOI":"10.1097\/COH.0000000000000363"},{"key":"10.1016\/j.vaccine.2021.05.073_b0020","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1146\/annurev.med.60.042507.164323","article-title":"Towards and antibody-based HIV-1 vaccine","volume":"61","author":"Hoxie","year":"2010","journal-title":"Annu Red Med"},{"issue":"9","key":"10.1016\/j.vaccine.2021.05.073_b0025","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1089\/aid.2019.0239","article-title":"A Systematic Approach to HIV-1 Vaccine Immunogen Selection","volume":"36","author":"Bontempo","year":"2020","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.vaccine.2021.05.073_b0030","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/d41586-019-01085-x","article-title":"HIV not as simple as one, two, three","volume":"568","author":"Trkola","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2021.05.073_b0035","article-title":"HIV vaccines: gp120 and beyond","volume":"28","author":"Duarte","year":"2018","journal-title":"Nature Milestones"},{"key":"10.1016\/j.vaccine.2021.05.073_b0040","unstructured":"Big improvements in HIV vaccine development. Science Daily 05 February 2018."},{"issue":"1","key":"10.1016\/j.vaccine.2021.05.073_b0045","article-title":"Chinese Hamster Ovary cells for the production of recombinant glycoproteins","volume":"19","author":"Camire","year":"2000","journal-title":"Art Sci HyClone Lab"},{"key":"10.1016\/j.vaccine.2021.05.073_b0050","unstructured":"Freedom DG44 Kit (for transfection of CHO DG44 cells (cGMP banked) and development of stable cell lines for protein production. Life Technologies. Publication part number MAN0003649 revision 27 April 2011."},{"key":"10.1016\/j.vaccine.2021.05.073_b0055","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.chroma.2014.02.086","article-title":"Multimodal chromatography: Characterization of protein binding and selectivity enhancement through mobile phase modulators","volume":"1340","author":"Wolfe","year":"2014","journal-title":"J Chromatogr A"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2100668X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2100668X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:56:56Z","timestamp":1759402616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2100668X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":11,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0264410X2100668X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.05.073","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a platform-based approach for the clinical production of HIV gp120 envelope glycoprotein vaccine candidates","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.05.073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 KBI Biopharma, Inc. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}